Publication list of Akiko Miki as of July 7, 2021 (Only written in English)
I. Original Articles

1.

Imai H, Tetsumoto A, Yamada H, Hayashida M, Otsuka K, Miki A, Nakamura M. Intraoperative

three-dimensional fluorescein angiography-guided pars plana vitrectomy for branch retinal vein
occlusion. Retin Cases Brief Rep. 2020 Nov 25. Epub ahead of print.
2.

Shijo T, Sakurada Y, Tanaka K, Miki A, Yoneyama S, Machida Y, Chubachi A, Wakatsuki Y,Sugiyama A, Onoe H, Kikushima W, Mori R, Kashiwagi K. Drusenoid Pigment Epithelial Detachment:
Genetic and Clinical Characteristics. Int J Mol Sci. 2021 Apr 15;22(8):4074.
3.

Maki H, Mori S, Imai H, Yamada H, Otsuka K, Miki A, Kusuhara S, Nakamura M. Autologous

Scleral Pocket Technique for Ahmed Glaucoma Valve Implantation with Pars Plana Tube Insertion for
Neovascular Glaucoma. J Clin Med. 2021 Apr 10;10(8):1606.
4.

Yamada H, Imai H, Tetsumoto A, Hayashida M, Otsuka K, Miki A, Kusuhara S, Nakamura M.

Cystotomy with or without fibrinogen clot removal for refractory cystoid macular edema secondary tobranch retinal vein occlusion. Sci Rep. 2021 Apr 19;11(1):8460.
5.

Ishikawa H, Uchida K, Takesue Y, Mori J, Kinoshita T, Morikawa S, Okamoto F, Sawada T, OhjiM, Kanda T, Takeuchi M, Miki A, Kusuhara S, Ueda T, Ogata N, Sugimoto M, Kondo M, Yoshida S,Ogata T, Kimura K, Mitamura Y, Jujo T, Takagi H, Terasaki H, Sakamoto T, Sugisawa T, Komuku Y,Gomi F. Clinical Characteristics and Outcomes in 314 Japanese Patients with Bacterial
Endophthalmitis: A Multicenter Cohort Study from J-CREST. Pathogens. 2021 Mar 24;10(4):390.
6.

Kim KW, Kusuhara S, Katsuyama-Yoshikawa A, Nobuyoshi S, Kitamura M, Mori S, Sotani N,Ueda K, Matsumiya W, Miki A, Kurimoto T, Imai H, Nakamura M. Changes in Gene Expression
Profiling and Phenotype in Aged Multidrug Resistance Protein 4-Deficient Mouse Retinas.
Antioxidants (Basel). 2021 Mar 15;10(3):455.
7.

Chubachi A, Miki A(corresponding author), Hayashida M, Sakamoto M, Imai H, Kusuhara S,Nakamura M. Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence
Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline
Visual Acuity. Pharmaceuticals (Basel). 2021 Mar 28;14(4):303.
8.

Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, Nakamura M, Tsujikawa A.

Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid
neovasculopathy. PLoS One. 2021 Mar 23;16(3):e0248760.
9.

Maki H, Imai H, Yamada H, Tetsumoto A, Hayashida M, Otsuka K, Miki A, Nakamura M. Thelong-term effect of cystotomy with fibrinogen clot removal for a cystoid macular edema secondary toidiopathic macular telangiectasia type 1: a case report. Retin Cases Brief Rep. 2021 Jan 4;Publish
Ahead of Print.
10. Hayashida M, Miki A(corresponding author), Nakai S, Matsumiya W, Imai H, Kusuhara S,Nakamura M. Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy inpatients with central serous chorioretinopathy with good baseline visual acuity. PLoS One. 2020 Oct
12;15(10):e0240557.
11. Hayashida M, Miki A (corresponding author), Shigeru Honda, Makoto Nakamura. Comparison
between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guidedhalf-time photodynamic therapy for central serous chorioretinopathy. Photodiagnosis Photodyn Ther.
Online ahead of print.
12. Hayashida M, Miki A (corresponding author), Nakai S, Matsumiya W, Imai H, Kusuhara S,Honda S, Nakamura M. Genetic factors associated with treatment response to reduced-fluence
photodynamic therapy for chronic central serous chorioretinopathy. Mol Vis. 2020;26:505-509.
13. Mori S, Kurimoto T, Miki A, Maeda H, Kusuhara S, Nakamura M. Aqp9 Gene Deletion Enhances
Retinal Ganglion Cell (RGC) Death and Dysfunction Induced by Optic Nerve Crush: Evidence that
Aquaporin 9 Acts as an Astrocyte-to-Neuron Lactate Shuttle in Concert with Monocarboxylate
Transporters To Support RGC Function and Survival. Mol Neorobiol. Online ahead of print.
14. Ashina M, Fujioka K, Ueda K, Miki A, Iijima K. Aggressive posterior retinopathy of prematurity
in a preterm infant with congenital hyperinsulinemia without persistent hyperglycemia. Pediatr
Neonatol. Online ahead of print.
15. Imai H, Tetsumoto A, Yamada H, Hayashida M, Otsuka K, Miki A, Kusuhara S, Nakamura M.
The long-term effect of cystotomy with or without the fibrinogen clot removal for the refractory cystoid
macular edema secondary to diabetic retinopathy. Retina. Online ahead of print.
16. Imai H, Tetsumoto A, Inoue S, Takano F, Yamada H, Hayashida M, Otsuka K, Miki A, Kusuhara
S, Nakamura M. Intraoperative Three-Dimensional Fluorescein Angiography-Guided Pars Plana
Vitrectomy for the Treatment of Proliferative Diabetic Retinopathy: The Maximized Utility of theDigital Assisted Vitrectomy.Retina 2020 published ahead of print
17. Katsuyama A, Kusuhara S, Asahara SI, Nakai SI, Mori S, Matsumiya W, Miki A, Kurimoto T,
Imai H, Kido Y, Ogawa W, Nakamura M. En face slab optical coherence tomography imaging
successfully monitors progressive degenerative changes in the innermost layer of the diabetic retina.
BMJ Open Diabetes Res Care. 2020;8(1): e001120.
18. Balikova I, Postelmans L, Pasteels B, Coquelet P, Catherine J, Efendic A, Hosoda Y, Miyake M,Yamashiro K; ANGEL study group members (Akiko Miki), Thienpont B, Lambrechts D. Geneticbiomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related maculardegeneration. BMJ Open Ophthalmol. 2019 e000273.
19. Ueda K, Miki A (corresponding author), Nakai S, Yanagisawa S, Nomura K, Nakamura M.
Prediction of severe retinopathy of prematurity using the weight gain, insulin-like growth factor 1, andneonatal retinopathy of prematurity algorithm in a Japanese population of preterm infants. Jpn JOphthalmol. 2020;64(2):223-227.
20. Hosoda Y, Miyake M, Schellevis RL, Boon CJF, Hoyng CB, Miki A, Meguro A, Sakurada Y,Yoneyama S, Takasago Y, Hata M, Muraoka Y, Nakanishi H, Oishi A, Ooto S, Tamura H, Uji A,Miyata M, Takahashi A, Ueda-Arakawa N, Tajima A, Sato T, Mizuki N, Shiragami C, Iida T, Khor CC,Wong TY, Yamada R, Honda S, de Jong EK, Hollander AID, Matsuda F, Yamashiro K, Tsujikawa A.
Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central
serous chorioretinopathy. Commun Biol. 2019;2:468.
21. Tetsumoto A, Imai H, Hayashida M, Otsuka K, Matsumiya W, Miki A, Nakamura M. The
comparison of the surgical outcome of 27-gauge pars plana vitrectomy for primary rhegmatogenous
retinal detachment between air and SF6 gas tamponade. Eye (Lond). 2020;34(2):299-306.
22. Sakurada Y, Tanaka K, Miki A, Matsumoto H, Kawamura A, Mukai R, Akiyama H, Honda S,Mori R, Iijima H. Clinical characteristics of cuticular drusen in the Japanese population. Jpn J

Ophthalmol. 2019;63(6):448-456.
23. Hayashida M, Miki A (corresponding author), Keiko Otsuka, Hisanori Imai, Atsushi Azumi,
Makoto Nakamura. Impact of Early Vitrectomy for Dense Vitreous Hemorrhage of Unknown Etiology.
Ophthalmologica 2019;242(4):234-238.
24. Nakai S, Matsumiya W, Miki A, Honda S, Nakamura M. Association of an age-related
maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept
combined with photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol.
2019;63(5):389-395.
25. Miki A, Yamada Y, Nakamura M. The Size of the Foveal Avascular Zone Is Associated withFoveal Thickness and Structure in Premature Children. J Ophthalmol 2019:8340729. 査読有
26. Tetsumoto A, Imai H, Otsuka K, Matsumiya W, Miki A, Nakamura M. Clinical factors
contributing to postoperative aqueous flare intensity after 27-gauge pars plana vitrectomy for theprimary rhegmatogenous retinal detachment. Jpn J Ophthalmol. 2019;63(4):317-321. 査読有
27. Miki A, Sakurada Y, Tanaka K, Semba K, Mitamura Y, Yuzawa M, Tajima A, Nakatochi M,
Yamamoto K, Matsuo K, Imoto I, Honda S. Genome-Wide Association Study to Identify a New
Susceptibility Locus for Central Serous Chorioretinopathy in the Japanese Population. Invest
Ophthalmol Vis Sci. 2018;59(13):5542-5547. 査読有
28. Nakai S, Matsumiya M, Otsuka K, Miki A, Nakamura M, Honda S. The 24-month outcomes ofintravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. JpnJ Ophthalmol. 2019;63(1):100-108. 査読有
29. Imai H, Otsuka K, Tetsumoto A, Miki A, Nakamura M. Effectiveness of en bloc removal of
fibrinogen-rich component of cystoid lesion for the treatment of cystoid macular edema. Retina. 2018
Epub ahead of print 査読有
30. Miki A, Fujihara M, Yoshida A, Nakamura M, Azumi A. A case of bilateral vasculitis associatedwith pineal germinoma. Am J Ophthalmol Case Rep. 2018;11:142-145. 査読有
31. Otsuka K, Imai H, Fujii A, Miki A, Tagami M, Azumi A, Nakamura M. Comparison of 25- and27-Gauge Pars Plana Vitrectomy in Repairing Primary Rhegmatogenous Retinal Detachment. JOphthalmol. 2018:7643174. 査読有
32. Hosoda Y, Yoshikawa M, Miyake M, Miki A, et al. CFH and VIPR2 as susceptibility loci inchoroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci
2018;115(24):6261-6266. 査読有
33. Obata S, Miki A (corresponding author), Imai H, Nakamura M. Bilateral corneal denting aftersurgery under general anesthesia: A case report. Am J Ophthalmol Case Rep. 2018, 10:290-292. 査読有34. Miki A, Honda S, Inoue Y, Yamada Y, Nakamura M. Foveal Depression and Related Factors inPatients with a History of Retinopathy of Prematurity. Ophthalmologica. 2018, 9:1-5.
35. Iwakawa Y, Imai H, Kaji H, Mori Y, Ono C, Otsuka K, Miki A, Oishi M. Autologous
Transplantation of the Internal Limiting Membrane for Refractory Macular Hole following Ruptured
Retinal Arterial Macroaneurysm: A Case Report. Case Rep Ophthalmol. 2018, 1;9(1):113-119.
36. Nakano Y, Miki A, Honda S, Nakamura M. Polypoidal Choroidal Vasculopathy Associated with

Optic Disc Coloboma. Case Rep Ophthalmol. 2018, 9;9(1):92-95.
37. Tetsumoto A, Imai H, Miki A, Nakamura M. A Case of Retinal Metastasis of Laryngeal
Squamous Cell Carcinoma with Histopathologic Confirmation by Vitrectomy-assisted En Block
Extraction. Retin Cases Brief Rep. 2017, [Epub ahead of print].
38. Sugiyama A, Sakurada Y, Honda S, Miki A, Matsumiya W, Yoneyama S, Kikushima W, Iijima H.
Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal
Ranibizumab. Ophthalmologica. 2018, 239(1):52-59.
39. Otsuka K, Imai H, Miki A, Nakamura M. Impact of postoperative positioning on the outcome ofpars plana vitrectomy with gas tamponade for primary rhegmatogenous retinal detachment: comparison
between supine and prone positioning. Acta Ophthalmol. 2018, 96(2):e189-e194.
40. Yamashiro K, Mori K, Honda S, Miki A, et al. A prospective multicenter study on genome wideassociations to ranibizumab treatment outcome for age-related macular degeneration. Sci Rep. 2017,23;7(1):9196.
41. Nakai S, Honda S, Matsumiya W, Miki A, Nakamura M. ARMS2 variants may predict the 3-year
outcome of photodynamic therapy for wet age-related macular degeneration. Mol Vis. 2017, 26;23:514519.
42. Nakai S, Honda S, Miki A, Matsumiya W, Nakamura M Comparison of the 12-Month Outcomesof Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal
Vasculopathy. Ophthalmologica. 2017, 237(3):123-127.
43. Honda S, Miki A, Kusuhara S, Imai H, Nakamura M Choroidal Thickness of Central Serous
Chorioretinopathy Secondary to Corticosteroid Use. Retina. 2017, 37(8):1562-1567.
44. Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M. Oneyear outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic
therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017, 255(3):541548.
45. Momozawa Y, Akiyama M, Kamatani Y, Miki A, et al. Low-frequency coding variants in CETPand CFB are associated with susceptibility of exudative age-related macular degeneration in theJapanese population. Hum Mol Genet. 2016, 15;25(22):5027-5034.
46. Akashi A, Miki A, Kanamori A, Nakamura M. Aquaporin 9 expression is required for l-lactate tomaintain retinal neuronal survival. 2015, Neurosci Lett. 589:185-90.
47. Yanagisawa S, Sakurada Y, Miki A, Matsumiya W, Imoto I, Honda S. The association of elastin
gene variants with two angiographic subtypes of polypoidal choroidal vasculopathy. PLoS One. 2015,
16;10(3): e0120643.
48. Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M.
Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical
Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24
Months of Follow-Up. Ophthalmologica. 2015, 234(1):33-9.
49. Enomoto H, Miki A, Matsumiya W, Honda S. Evaluation of Oxygen Supplementation Status as aRisk Factor Associated with the Development of Severe Retinopathy of Prematurity. Ophthalmologica.
2015, 234(3):135-8.
50. Miki A, Knamori A, Nakamura M, Matsumoto Y, Mizokami J, Negi A. The expression ofsyntaphilin is down-regulated in the optic nerve after axonal injury. Exp Eye Res.2014, 129:38-47.

51. Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in thecomplement factor H gene confer genetic susceptibility to central serous chorioretinopathy.
Ophthalmology 2014, 121(5):1067-72.
52. Matsumiya W, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Evaluation of clinical andgenetic indicators for the early response to intravitreal ranibizumab in exudative age-related maculardegeneration. Pharmacogenomics. 2014, 15(6):833-43.
53. Honda S, Miki A, Yanagisawa S, Matsumiya W, Nagai T, Tsukahara Y. Comparison of theOutcomes of Photodynamic Therapy between Two Angiographic Subtypes of Polypoidal Choroidal
Vasculopathy. Ophthalmologica. 2014, 232(2):92-6.
54. Miki A, Honda S, Kondo N, Negi A. The association of age-related maculopathy susceptibility 2(ARMS2) and complement factor H (CFH) variants with two angiographic subtypes of polypoidal
choroidal vasculopathy. Ophthalmic Genet. 2014, 34(3):146-50.
55. Miki A, Kanamori A, Negi A, Naka M, Nakamura M. Loss of aquaporin 9 expression adversely
affects the survival of retinal ganglion cells. Am J Pathol. 2014, 182(5):1727-39.
56. Miki A, Honda S, Kojima H, Nishizaki M, Nagai T, Fujihara M, Uenishi M, Kita M, Kurimoto Y,Negi A; Hyogo Macular Disease Study Group. Visual outcome of photodynamic therapy for typicalneovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years offollow-up. Jpn J Ophthalmol. 2013, 57(3):301-7.
57. Miki A, Honda S, Nagai T, Tsukahara Y, Negi A. Effects of oral bisphosphonates on myopic
choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy andphotodynamic therapy. A pilot study. Br J Ophthalmol. 2013, 97(6):770-4.
58. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS,Campochiaro PA, Green JJ. Long-term suppression of ocular neovascularization by intraocular
injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials. 2013,34(30):7544-51.
59. Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima e Silva R,Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, Campochiaro PA.
Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release. 2013,
172(3):625-33.
60. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A. A
common complement C3 variant is associated with protection against wet age-related maculardegeneration in a Japanese population. PLoS One. 2011, 6(12):e28847.
61. Yanagisawa S, Kondo N, Miki A, Matsumiya W, Kusuhara S, Tsukahara Y, Honda S, Negi A.
Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in thehereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene
(ARMS2). Mol Vis. 2011, 17:3574-82.
62. Miki A, Miki K, Ueno S, Wersinger DM, Berlinicke C, Shaw GC, Usui S, Wang Y, Zack DJ,Campochiaro PA. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors organglion cells. J Cell Physiol. 2010, 224(1):262-72.
63. Usui S, Oveson BC, Lee SY, Jo YJ, Yoshida T, Miki A, Miki K, Iwase T, Lu L, Campochiaro PA.
NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. J Neurochem. 2009,110(3):1028-37.

64. Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA. Effects of intraocularranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor.
Ophthalmology. 2009, 116(9):1748-54.